First evidence that bone marrow cells contribute to the construction of tissue-engineered vascular autografts in vivo

Circulation

Volumn 108, Issue 14, 2003, Pages 1729-1734

  Matsumura, Goki ^a   Miyagawa Tomita, Sachiko ^a   Shin'Oka, Toshiharu ^a   Ikada, Yoshito ^b   Kurosawa, Hiromi ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b SUZUKA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Cells; Polymers; Surgery; Tissue engineering

Indexed keywords

ALPHA ACTIN; ANGIOPOIETIN 1; ANTIGEN; ANTIGEN FLK1; ANTIGEN TIE2; BLOOD CLOTTING FACTOR 8; CD146 ANTIGEN; CD31 ANTIGEN; CD34 ANTIGEN; CELL MARKER; MEMBRANE PROTEIN; PROTEIN SM1; PROTEIN SM2; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ARTICLE; AUTOGRAFT; BIODEGRADABILITY; BLOOD VESSEL GRAFT; BONE MARROW CELL; CARDIOVASCULAR SURGERY; CELL LINEAGE; CONGENITAL HEART MALFORMATION; CONTROLLED STUDY; DIAGNOSTIC VALUE; DOG; DOSE TIME EFFECT RELATION; ENDOTHELIUM CELL; FLUORESCENCE; HISTOCOMPATIBILITY; HISTOGENESIS; IMMUNOHISTOCHEMISTRY; INFERIOR CAVA VEIN; NONHUMAN; PRIORITY JOURNAL; REOPERATION; TISSUE ENGINEERING;

ABSORBABLE IMPLANTS; ANIMALS; BIOCOMPATIBLE MATERIALS; BLOOD VESSELS; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; CELL DIFFERENTIATION; DOGS; ENDOTHELIUM, VASCULAR; FOLLOW-UP STUDIES; GROWTH SUBSTANCES; MUSCLE, SMOOTH, VASCULAR; STEM CELLS; TISSUE ENGINEERING; TRANSPLANTATION, AUTOLOGOUS;

EID: 0141988860     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000092165.32213.61     Document Type: Article

References (32)

1. Kirklin J, Barratt-Boyes B. Ventricular Septal Defect and Pulmonary Stenosis or Atresia. New York, NY: Churchill Livingstone: 1993.
2. Watanabe M, Shin'oka T, Tohyama S, et al. Tissue-engineered vascular autograft: inferior vena cava replacement in a dog model. Tissue Eng. 2001;7:429-439.
3. Shinoka T, Breuer CK, Tanel RE, et al. Tissue engineering heart valves: valve leaflet replacement study in a lamb model. Ann Thorac Surg. 1995;60:S513-S516.
4. Shinoka T, Ma PX, Shum-Tim D, et al. Tissue-engineered heart valves: autologous valve leaflet replacement study in a lamb model. Circulation. 1996;94:II-164-II-168.
5. Shinoka T, Shum-Tim D, Ma PX, et al. Tissue-engineered heart valve leaflets: does cell origin affect outcome? Circulation. 1997;96:II-102-II-107.
6. Shinoka T, Shum-Tim D, Ma PX, et al. Creation of viable pulmonary artery autografts through tissue engineering. J Thorac Cardiovasc Surg. 1998;115:536-545 [Discussion pp 545-536].
7. Shin'oka T, Imai Y, Ikada Y. Transplantation of a tissue-engineered pulmonary artery. N Engl J Med. 2001;344:532-533.
8. Langer R, Vacanti JP. Tissue engineering. Science. 1993;260:920-926.
9. Takahashi T, Kalka C, Masuda H, et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med. 1999;5:434-438.
10. Shintani S, Murohara T, Ikeda H, et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation. 2001;103:2776-2779.
11. Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res. 1999;85:221-228.
12. Noishiki Y, Tomizawa Y, Yamane Y, et al. Autocrine angiogenic vascular prosthesis with bone marrow transplantation. Nat Med. 1996;2:90-93.
13. Ishida A, Murray J, Saito Y, et al. Expression of vascular endothelial growth factor receptors in smooth muscle cells. J Cell Physiol. 2001;188:359-368.
14. Matsunaga T, Warltier DC, Weihrauch DW, et al. Ischemia-induced coronary collateral growth is dependent on vascular endothelial growth factor and nitric oxide. Circulation. 2000;102:3098-3103.
15. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275:964-967.
16. Asahara T, Chen D, Takahashi T, et al. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF- induced postnatal neovascularization. Circ Res. 1998;83:233-240.
17. + bone marrow cells. Blood. 2000;95:581-585.
18. Kamihata H, Matsubara H, Nishiue T, et al. Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation. 2000;104:1046-1052.
19. Grosskreutz CL, Anand-Apte B, Duplaa C, et al. Vascular endothelial growth factor-induced migration of vascular smooth muscle cells in vitro. Microvasc Res. 1999;58:128-136.
20. Gerber HP, McMurtrey A, Kowalski J, et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway: requirement for Flk-1/KDR activation. J Biol Chem. 1998;273:30336-30343.
21. Davis S, Aldrich TH, Jones PF, et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell. 1996;87:1161-1169.
22. Solovey A, Lin Y, Browne P, et al. Circulating activated endothelial cells in sickle cell anemia. N Engl J Med. 1997;337:1584-1590.
23. Frangogiannis NG, Michael LH, Entman ML. Myofibroblasts in reperfused myocardial infarcts express the embryonic form of smooth muscle myosin heavy chain (SMemb). Cardiovasc Res. 2000;48:89-100.
24. Kuro-o M, Nagai R, Tsuchimochi H, et al. Developmentally regulated expression of vascular smooth muscle myosin heavy chain isoforms. J Biol Chem. 1989;264:18272-18275.
25. Kuro-o M, Nagai R, Nakahara K, et al. cDNA cloning of a myosin heavy chain isoform in embryonic smooth muscle and its expression during vascular development and in arteriosclerosis. J Biol Chem. 1991;266:3768-3773.
26. Shi Q, Rafii S, Wu MH, et al. Evidence for circulating bone marrow-derived endothelial cells. Blood. 1998;92:362-367.
27. McKay R. Stem cells: hype and hope. Nature. 2000;406:361-364.
28. Suri C, Jones PF, Patan S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell. 1996;87:1171-1180.
29. Shalaby F, Ho J, Stanford WL, et al. A requirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis. Cell. 1997;89:981-990.
30. Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature. 1995;376:62-66.
31. Asahara T, Takahashi T, Masuda H, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 1999;18:3964-3972.
32. Takakura N, Watanabe T, Suenobu S, et al. A role for hematopoietic stem cells in promoting angiogenesis. Cell. 2000;102:199-209.